News
EDTXF
0.700
NaN%
--
Spectral Medical Provides Update Following In-Person FDA 100-Day Meeting for PMX PMA
Barchart · 09/11 06:00
Spectral Medical GAAP EPS of $0.00 beats by $0.01, revenue of $0.62M beats by $0.02M
Seeking Alpha · 08/07 11:56
Stocks in play: Spectral Medical Inc.
Barchart · 08/07 10:04
Spectral Medical Inc. Announces Results of Annual and Special Meeting of Shareholders
Barchart · 06/09 15:18
Spectral Medical reports Q4 results
Seeking Alpha · 03/26 14:46
Spectral Medical Advances PMX Toward FDA Submission After Positive Tigris Results
TipRanks · 03/26 12:35
Spectral Medical’s Tigris Trial Shows Survival Benefit in Endotoxic Septic Shock
TipRanks · 03/24 11:59
Spectral Medical Pushes Back PMX-20R FDA Filing to Add 12-Month Mortality Data
TipRanks · 02/26 15:58
Stocks in play: Spectral Medical Inc
Barchart · 02/26 14:33
Spectral Medical Provides Update on PMA Submission Timing for PMX-20R
Barchart · 02/26 06:30
Spectral Medical Reports Positive Trial Results and Revenue Growth
TipRanks · 11/21/2025 04:06
Spectral Medical Reports Positive Tigris Trial Results and Prepares for FDA Submission
TipRanks · 11/07/2025 13:09
Spectral Medical Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Barchart · 11/07/2025 06:30
More
Webull provides a variety of real-time EDTXF stock news. You can receive the latest news about Spectral Med through multiple platforms. This information may help you make smarter investment decisions.
About EDTXF
Spectral Medical Inc. is a Canada-based late-stage theranostic company focused on advancing therapeutic solutions for sepsis and septic shock. The Company develops and commercializes Toraymyxin (PMX), a therapeutic hemoperfusion device designed to remove endotoxins from the bloodstream, which are a major cause of sepsis. The Company also offers the Endotoxin Activity Assay (EAA), the diagnostic test for detecting endotoxin levels in blood, and it provides an endotoxin activity result normally between 0.0 and 1.0. It provides reagents for both research and commercial applications. Their product line includes monoclonal antibodies and recombinant proteins, which are essential for developing advanced diagnostic tools. Additionally, the Company is conducting the Tigris Clinical Trial, a confirmatory study evaluating PMX in combination with standard care versus standard care alone, using Bayesian statistical analysis.